###begin article-title 0
###xml 41 44 41 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink">nef</italic>
###xml 53 58 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Phenotype and envelope gene diversity of nef-deleted HIV-1 isolated from long-term survivors infected from a single source
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 118 121 118 121 <italic xmlns:xlink="http://www.w3.org/1999/xlink">nef</italic>
###xml 383 387 383 387 <italic xmlns:xlink="http://www.w3.org/1999/xlink">nef </italic>
###xml 431 439 431 439 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 512 515 512 515 <italic xmlns:xlink="http://www.w3.org/1999/xlink">nef</italic>
###xml 581 584 581 584 <italic xmlns:xlink="http://www.w3.org/1999/xlink">nef</italic>
###xml 630 634 630 634 <italic xmlns:xlink="http://www.w3.org/1999/xlink">env </italic>
###xml 142 177 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
###xml 179 184 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 456 461 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 593 598 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
The Sydney blood bank cohort (SBBC) of long-term survivors consists of multiple individuals infected with attenuated, nef-deleted variants of human immunodeficiency virus type 1 (HIV-1) acquired from a single source. Long-term prospective studies have demonstrated that the SBBC now comprises slow progressors (SP) as well as long-term nonprogressors (LTNP). Convergent evolution of nef sequences in SBBC SP and LTNP indicates the in vivo pathogenicity of HIV-1 in SBBC members is dictated by factors other than nef. To better understand mechanisms underlying the pathogenicity of nef-deleted HIV-1, we examined the phenotype and env sequence diversity of sequentially isolated viruses (n = 2) from 3 SBBC members.
###end p 3
###begin title 4
Results
###end title 4
###begin p 5
###xml 681 685 681 685 <italic xmlns:xlink="http://www.w3.org/1999/xlink">env </italic>
###xml 834 838 834 838 <italic xmlns:xlink="http://www.w3.org/1999/xlink">env </italic>
###xml 112 117 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 337 342 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 826 833 <span type="species:ncbi:9606">patient</span>
The viruses characterized here were isolated from two SP spanning a three or six year period during progressive HIV-1 infection (subjects D36 and C98, respectively) and from a LTNP spanning a two year period during asymptomatic, nonprogressive infection (subject C18). Both isolates from D36 were R5X4 phenotype and, compared to control HIV-1 strains, replicated to low levels in peripheral blood mononuclear cells (PBMC). In contrast, both isolates from C98 and C18 were CCR5-restricted. Both viruses isolated from C98 replicated to barely detectable levels in PBMC, whereas both viruses isolated from C18 replicated to low levels, similar to those isolated from D36. Analysis of env by V1V2 and V3 heteroduplex tracking assay, V1V2 length polymorphisms, sequencing and phylogenetic analysis showed distinct intra- and inter-patient env evolution.
###end p 5
###begin title 6
Conclusion
###end title 6
###begin p 7
###xml 25 29 25 29 <italic xmlns:xlink="http://www.w3.org/1999/xlink">env </italic>
###xml 61 65 61 65 <italic xmlns:xlink="http://www.w3.org/1999/xlink">nef </italic>
###xml 87 95 87 95 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 112 115 112 115 <italic xmlns:xlink="http://www.w3.org/1999/xlink">nef</italic>
###xml 124 129 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Independent evolution of env despite convergent evolution of nef may contribute to the in vivo pathogenicity of nef-deleted HIV-1 in SBBC members, which may not necessarily be associated with changes in replication capacity or viral coreceptor specificity.
###end p 7
###begin title 8
Background
###end title 8
###begin p 9
###xml 234 235 234 235 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 236 237 236 237 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 304 308 304 308 <italic xmlns:xlink="http://www.w3.org/1999/xlink">nef </italic>
###xml 312 315 312 315 <italic xmlns:xlink="http://www.w3.org/1999/xlink">nef</italic>
###xml 734 735 734 735 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 837 838 837 838 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 839 840 839 840 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 944 947 944 947 <italic xmlns:xlink="http://www.w3.org/1999/xlink">nef</italic>
###xml 1056 1060 1056 1060 <italic xmlns:xlink="http://www.w3.org/1999/xlink">nef </italic>
###xml 1154 1157 1154 1157 <italic xmlns:xlink="http://www.w3.org/1999/xlink">nef</italic>
###xml 1257 1258 1257 1258 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 1421 1424 1421 1424 <italic xmlns:xlink="http://www.w3.org/1999/xlink">nef</italic>
###xml 147 152 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 370 375 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 716 721 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 820 825 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1267 1272 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1443 1448 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
The Sydney blood bank cohort (SBBC) of long-term survivors (LTS) consists of multiple individuals who became infected with an attenuated strain of HIV-1 via contaminated blood products from a common blood donor between 1981 and 1984 [1-3]. Viral attenuation has been attributed to gross deletions in the nef and nef/long-terminal repeat (LTR) overlapping regions of the HIV-1 genome. Despite being infected from a single source, long-term prospective studies on SBBC members demonstrated that the cohort now consists of subjects with slow disease progression (SP), as well as individuals who remain true long-term nonprogressors (LTNP) and antiretroviral therapy-naive with stable CD4 counts and low or undetectable HIV-1 RNA levels [4]. Three SBBC members (one SP and two LTNP) have since died from causes unrelated to HIV-1 infection [3,4]. Although the cohort members had differing clinical courses, a comprehensive longitudinal analysis of nef/LTR sequences in the SBBC donor and four of the transfusion recipients demonstrated a convergent pattern of nef sequence evolution, characterized by progressive sequence deletions evolving toward a minimal nef/LTR structure that retains only the key sequence elements that are required for viral replication [4]. Thus, HIV-1 pathogenicity in SBBC members is dictated by viral and/or host determinants other than those that impose a unidirectional selection pressure on the nef/LTR region of the HIV-1 genome.
###end p 9
###begin p 10
###xml 10 14 10 14 <italic xmlns:xlink="http://www.w3.org/1999/xlink">env </italic>
###xml 144 145 144 145 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 146 147 146 147 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 249 250 249 250 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 251 253 251 253 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 265 267 265 267 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 575 577 575 577 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 578 580 578 580 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 1014 1016 1014 1016 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 1017 1019 1017 1019 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 1134 1135 1134 1135 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 1161 1165 1161 1165 <italic xmlns:xlink="http://www.w3.org/1999/xlink">env </italic>
###xml 4 9 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 111 116 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 151 156 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 286 291 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 401 406 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 473 478 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 614 619 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 792 797 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 843 848 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 863 868 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1070 1075 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1155 1160 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1224 1229 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
The HIV-1 env gene, which encodes the viral envelope glycoproteins (Env) is a significant viral determinant in HIV-1 pathogenesis [reviewed in [5-7]]. HIV-1 Env initiates viral entry via binding to CD4 and subsequently to a coreceptor, either CCR5 [8-12] or CXCR4 [13]. CCR5-using (R5) HIV-1 strains predominate at early, asymptomatic stages of infection. In 40-50% of infected adults, progression of HIV-1 infection is accompanied by a switch in coreceptor specificity to HIV-1 variants able to use CXCR4 or both CCR5 and CXCR4 for entry (X4 or R5X4 strains, respectively) [14,15]. A switch in the specificity of HIV-1 Env from R5 to X4 or R5X4 is considered an indicator of poor prognosis, partly because it increases the number of CD4+ cells that are susceptible to cytolytic infection by HIV-1, and is associated with rapid progression of HIV-1 infection. R5 HIV-1 variants are present exclusively in the remaining 50-60% of infected individuals who progress to AIDS, without switching coreceptor specificity [16,17], and exert pathogenic effects that contribute to HIV-1 progression via mechanisms that remain poorly understood [5]. Thus, changes in HIV-1 env that affect viral tropism are important for progression of HIV-1 infection.
###end p 10
###begin p 11
###xml 47 51 47 51 <italic xmlns:xlink="http://www.w3.org/1999/xlink">env </italic>
###xml 283 285 283 285 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 286 288 286 288 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 399 401 399 401 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 402 404 402 404 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 529 533 529 533 <italic xmlns:xlink="http://www.w3.org/1999/xlink">env </italic>
###xml 633 635 633 635 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 1201 1205 1201 1205 <italic xmlns:xlink="http://www.w3.org/1999/xlink">env </italic>
###xml 1264 1266 1264 1266 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 1636 1638 1636 1638 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 105 110 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 266 271 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 523 528 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1047 1052 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1285 1290 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1336 1341 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1434 1439 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1565 1573 <span type="species:ncbi:9606">patients</span>
###xml 1698 1703 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1733 1741 <span type="species:ncbi:9606">patients</span>
Analysis of inter- and intra-host evolution of env sequence has provided important insights relevant for HIV-1 transmission and progression. While several reports showed an inverse relationship between the rate and extent of viral diversification and progression of HIV-1 infection [18-25], other studies demonstrated that disease progression is associated with increasing rates of viral diversity [26-28]. A later study made significant headway in reconciling these conflicting studies by identifying 3 distinct phases of HIV-1 env sequence diversity and divergence during the asymptomatic period preceding the development of AIDS [29]; an early phase of variable duration with linear increases (approximately 1% per year) in both viral divergence and diversity; an intermediate phase characterized by a continued increase in viral divergence but with a stabilisation or decline in viral diversity; and a late phase characterized by a stabilisation of viral divergence and a continued stability or decline in viral diversity. The emergence of X4 HIV-1 variants often coincided with transition between the early and intermediate phases. More recent studies identified convergent sequence evolution in env during the early phase toward a common ancestral sequence [30], suggesting that HIV-1 recovers certain ancestral features early in HIV-1 infection that most likely serve to restore viral fitness. However, other studies examining HIV-1 progression in individuals harbouring only R5 variants showed an increase in viral diversity in viral isolates obtained from patients with AIDS compared to isolates from asymptomatic individuals [31], raising the possibility that selection pressures driving HIV-1 evolution may be distinct in patients who maintain R5 viral variants compared to those who experience a coreceptor switch.
###end p 11
###begin p 12
###xml 61 64 61 64 <italic xmlns:xlink="http://www.w3.org/1999/xlink">nef</italic>
###xml 208 212 208 212 <italic xmlns:xlink="http://www.w3.org/1999/xlink">env </italic>
###xml 306 310 306 310 <italic xmlns:xlink="http://www.w3.org/1999/xlink">env </italic>
###xml 444 446 444 446 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 477 485 477 485 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ex vivo </italic>
###xml 614 616 614 616 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 682 690 682 690 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 707 710 707 710 <italic xmlns:xlink="http://www.w3.org/1999/xlink">nef</italic>
###xml 756 758 756 758 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 73 78 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 202 207 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 297 302 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 412 415 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 485 490 <span type="species:ncbi:9606">human</span>
###xml 510 515 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 719 748 <span type="species:ncbi:11723">simian immunodeficiency virus</span>
###xml 750 753 <span type="species:ncbi:11723?0.9432672590567327">SIV</span>
While the viral determinants underlying the pathogenicity of nef-deleted HIV-1 strains harbored by SBBC members are presently unknown, several lines of evidence support the hypothesis that evolution of HIV-1 env contributes to disease progression in this cohort; 1) compartmentalized evolution of HIV-1 V3 env sequence in cerebrospinal fluid (CSF) of the SBBC donor was shown to contribute to the development of HIV-associated dementia (HIVD) [32]; 2) enhanced cell killing in ex vivo human tissue cultures by HIV-1 isolates from the same SBBC subject was predicted to result from more efficient coreceptor usage [33]; and 3) increased Env-mediated fusion was shown to increase the in vivo pathogenicity of nef-deleted simian immunodeficiency virus (SIV) [34].
###end p 12
###begin p 13
###xml 39 43 39 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink">env </italic>
###xml 66 69 66 69 <italic xmlns:xlink="http://www.w3.org/1999/xlink">nef</italic>
###xml 148 152 148 152 <italic xmlns:xlink="http://www.w3.org/1999/xlink">env </italic>
###xml 533 537 533 537 <italic xmlns:xlink="http://www.w3.org/1999/xlink">env </italic>
###xml 686 690 686 690 <italic xmlns:xlink="http://www.w3.org/1999/xlink">env </italic>
###xml 732 736 732 736 <italic xmlns:xlink="http://www.w3.org/1999/xlink">env </italic>
###xml 768 772 768 772 <italic xmlns:xlink="http://www.w3.org/1999/xlink">nef </italic>
###xml 794 802 794 802 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 819 822 819 822 <italic xmlns:xlink="http://www.w3.org/1999/xlink">nef</italic>
###xml 33 38 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 78 83 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 678 685 <span type="species:ncbi:9606">patient</span>
###xml 831 836 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
To better understand the role of HIV-1 env in the pathogenesis of nef-deleted HIV-1 strains harbored by SBBC members, we examined the phenotype and env sequence diversity of sequential viruses isolated from 3 SBBC members. Isolates from the SBBC "donor" (subject D36; SP) were R5X4 phenotype and replicated to low levels in peripheral blood mononuclear cells (PBMC). In contrast, isolates from 2 SBBC "recipients" (subjects C98 and C18; SP and LTNP, respectively) were CCR5-restricted with variable replication kinetics. Analysis of env by V1V2 and V3 heteroduplex tracking assay, V1V2 length polymorphisms, sequencing and phylogenetic analysis showed distinct intra- and inter-patient env evolution. Thus, independent evolution of env despite convergent evolution of nef may contribute to the in vivo pathogenicity of nef-deleted HIV-1 in SBBC members, which may not necessarily be associated with changes in replication capacity or viral coreceptor specificity.
###end p 13
###begin title 14
Results and discussion
###end title 14
###begin title 15
Subjects
###end title 15
###begin p 16
###xml 145 146 145 146 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 147 148 147 148 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 149 151 149 151 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 263 264 263 264 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 804 806 803 805 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 807 809 806 808 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 1061 1062 1060 1061 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 1063 1064 1062 1063 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 1357 1358 1356 1357 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 205 210 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 366 371 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 543 548 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 913 918 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 999 1004 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1119 1124 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1206 1211 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1339 1344 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
The clinical history of the study subjects, results of laboratory studies and antiretroviral therapies have been described in detail previously [3,4,32]. The results of laboratory studies relevant for the HIV-1 isolates used in this study are summarized in Table 1. Briefly, the SBBC donor, subject D36 presented with HIVD in December 1998 after being infected with HIV-1 for 18 years without antiretroviral therapy. The development of HIVD coincided with a fall in the CD4 cell count to <200 cells/mul and the presence of high plasma and CSF HIV-1 RNA levels. The subject was placed on a highly active antiretroviral therapy (HAART) regimen of abacavir, nevirapine and zidovidine in January 1999, which suppressed plasma and CSF viral loads to below detectable levels and resolved the symptoms of HIVD [32,35]. As reported previously, transfusion recipient C98 commenced HAART in November 1999 after 16 years of HIV-1 infection, following a steady decline in CD4+ T-cells and a gradual increase in HIV-1 RNA from below detectable levels to 1500 RNA copies/ml [3,4]. He died in March 2002 of amyloidosis, which was not HIV-1 related. Likewise, transfusion recipient C18 died in 1995 of causes unrelated to HIV-1 infection. C18 remained antiretroviral therapy naive despite 12 years of infection, with stable CD4 cell counts and low plasma HIV-1 RNA levels [3]. Thus, subjects D36 and C98 showed evidence of slow progression while subject C18 remained a long-term nonprogressor.
###end p 16
###begin p 17
Subjects and laboratory studies
###end p 17
###begin p 18
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
aCD4+ T-cell levels were measured by flow cytometry.
###end p 18
###begin p 19
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 8 13 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 179 184 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
bPlasma HIV-1 RNA was measured using COBAS AMPLICOR monitor version 1.0 (Roche Molecular Diagnostic Systems, Branchburg, N.J.) prior to July 1999 and version 1.5 after July 1999. HIV-1 RNA levels of <400 copies/ml (version 1.0) or <50 copies/ml (version 1.5) were considered below detection. BD, below detection; N/A, not available.
###end p 19
###begin p 20
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c</sup>
cABC, abacavir; AZT, zidovudine; NVP, nevirapine; 3TC, lamivudine; d4T, stavudine; IND, indinavir.
###end p 20
###begin p 21
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">d</sup>
dSP, slow progressor; LTNP, long-term nonprogressor. Comprehensive laboratory data collected since 1993 and detailed clinical history of the study subjects has been published previously [3, 4, 32], which was used to classify subjects as SP or LTNP.
###end p 21
###begin p 22
###xml 82 83 82 83 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 0 5 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
HIV-1 isolated from PBMC on 2 consecutive occasions was used in this study (Table 1). The time between isolations ranged from 2 to 6 years. For the purpose of this report, the initial isolates are referred to as "early" isolates, and the subsequent isolates are referred to as "late" isolates (designated "E" and "L", respectively).
###end p 22
###begin title 23
Replication kinetics
###end title 23
###begin p 24
###xml 94 95 94 95 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 249 251 249 251 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1A</xref>
###xml 365 367 365 367 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1B</xref>
###xml 538 540 538 540 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1D</xref>
###xml 621 623 621 623 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1C</xref>
###xml 38 43 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 123 128 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 743 748 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 901 906 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
We first examined the capacity of the HIV-1 isolates to replicate in PHA-activated PBMC (Fig. 1). The R5 ADA and R5X4 89.6 HIV-1 strains were included as positive controls, and replicated rapidly to high levels peaking at day 7 post-infection (Fig. 1A). Both D36E and D36L viruses replicated to comparatively low levels, with similar kinetics as ADA and 89.6 (Fig. 1B). Both C18 viruses replicated with similar kinetics, but peak levels of replication by C18L were modestly higher (approximately 2-fold) than those achieved by C18E (Fig. 1D). In contrast, replication of C98E and C98L viruses was barely detectable (Fig. 1C). Since D36 and C98 were slow progressors and C18 was a LTNP, there was no association between replication kinetics of HIV-1 isolates in PBMC and disease progression in the study subjects. However, the results highlight the heterogeneity in replication capacity by nef-deleted HIV-1 strains isolated from multiple subjects infected from a single source.
###end p 24
###begin p 25
###xml 0 28 0 28 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Replication kinetics in PBMC</bold>
Replication kinetics in PBMC. PBMC were infected with equivalent amounts of each virus, as described in the Methods, and cultured for 28 days. Virus production in culture supernatants was measured by RT assays. Values shown are means from duplicate infections. Error bars represent standard deviations. Results are representative of two independent experiments using cells obtained from different donors.
###end p 25
###begin title 26
Coreceptor usage
###end title 26
###begin p 27
###xml 241 242 241 242 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 386 388 386 388 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2A</xref>
###xml 404 405 404 405 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 406 408 406 408 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 409 411 409 411 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 459 461 459 461 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 549 551 549 551 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2B</xref>
###xml 751 753 751 753 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 754 756 754 756 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 809 811 809 811 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 1035 1037 1035 1037 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 1412 1413 1412 1413 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 1540 1543 1540 1543 <italic xmlns:xlink="http://www.w3.org/1999/xlink">nef</italic>
###xml 1683 1686 1683 1686 <italic xmlns:xlink="http://www.w3.org/1999/xlink">nef</italic>
###xml 1739 1747 1739 1747 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 1865 1873 1865 1873 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 203 208 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1214 1219 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
The results of the preceding experiments suggest the existence of additional phenotypic changes that may contribute to altered replication capacity in PBMC. We therefore compared the coreceptor usage of HIV-1 isolates in Cf2-Luc cells (Fig. 2). The R5 ADA and R5X4 89.6 strains were included as positive controls and used CCR5 or both CCR5 and CXCR4 for virus entry, respectively (Fig. 2A), as expected [9,11,36]. Consistent with results of previous studies [32], D36E and D36L viruses were dual tropic and used CCR5 and CXCR4 for virus entry (Fig. 2B). C98E, C98L, C18E and C18L viruses used CCR5 only for virus entry. Replication of dual tropic D36E and D36L viruses in PBMC was abolished by preincubation of cells with the CXCR4 inhibitor AMD3100 [37,38], but was unaffected by the CCR5 inhibitor TAK-779 [39] (data not shown). This suggests that the viral quasispecies in D36 isolates are not a mixture containing R5 variants, and confirms previous studies that showed infection of PBMC by R5X4 viruses occurs primarily via CXCR4 [40]. Thus, D36 isolates are of R5X4 phenotype, and C18 and C98 isolates are of R5 phenotype. These results indicate that the presence of a functional nef gene is not required for HIV-1 to undergo a switch in coreceptor preference from R5 to R5X4. However, since D36 harbored R5X4 variants without antiretroviral therapy while remaining asymptomatic for at least 4 years (Table 1), the results suggest that acquisition of an R5X4 phenotype is not sufficient for rapid disease progression in the absence of nef. Moreover, the fact that C98 maintained an R5 virus that replicated poorly in PBMC, despite evidence of disease progression, suggests that nef-deleted viruses may acquire increased pathogenicity in vivo by mechanism(s) that are not necessarily associated with changes in coreceptor usage or enhanced replicative capacity in vitro.
###end p 27
###begin p 28
###xml 0 42 0 42 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Coreceptor usage by primary HIV-1 isolates</bold>
###xml 28 33 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 211 216 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Coreceptor usage by primary HIV-1 isolates. Cf2-Luc cells were transfected with pcDNA3-CD4 alone or cotransfected with pcDNA3-CD4 and pcDNA3 expressing CCR5 or CXCR4 and infected with equivalent amounts of each HIV-1 isolate as described in the Methods. Cell lysates were prepared at 48 h post-infection and assayed for luciferase activity. Data are expressed as means from duplicate infections. Error bars represent standard deviations. Similar results were obtained in three independent experiments.
###end p 28
###begin title 29
V1V2 and V3 HTA analysis
###end title 29
###begin p 30
###xml 84 92 84 92 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 166 175 166 175 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 176 177 176 177 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 64 69 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Changes in the dominant viral quasispecies may serve to augment HIV-1 pathogenicity in vivo without increasing replication capacity or changing coreceptor preference in vitro [5]. Therefore, to determine whether distinct viral variants are present in early and late D36, C18 and C98 viruses, Env V1V2 and V3 HTA analyses were conducted.
###end p 30
###begin p 31
###xml 43 45 43 45 <sup xmlns:xlink="http://www.w3.org/1999/xlink">32</sup>
###xml 121 122 121 122 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
###xml 127 128 127 128 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4</xref>
###xml 415 416 415 416 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
###xml 421 422 421 422 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4</xref>
###xml 510 511 510 511 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
###xml 516 517 516 517 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4</xref>
###xml 716 717 716 717 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
The V1V2 and V3 HTAs were conducted using [32P]-labelled probes generated from the R5 ADA Env or the X4 NL4-3 Env (Figs. 3 and 4; left and right panels, respectively). HTA negative controls consisted of reactions containing probe alone or mixed with homologous, unlabelled target DNA to identify homoduplexes. HTA positive controls consisted of ADA probe in reactions containing unlabelled NL4-3 or 89.6 Env (Figs. 3 and 4; left panels), or NL4-3 probe in reactions containing unlabelled ADA or 89.6 Env (Fig. 3 and 4, right panels) to identify heteroduplexes. V1V2 HTAs using either probe demonstrated that C98L contained 2 dominant variants that were distinct from the single, dominant species found in C98E (Fig. 3). Similarly, V1V2 HTAs with either probe demonstrated 2 dominant variants in D36L that were distinct from 4 variants found in D36E. V1V2 HTAs using the NL4-3 probe demonstrated 3 variants in C18L that were distinct from 4 variants found in C18E. However, the ADA probe appeared to be less sensitive for detecting distinct V1V2 variants in C18E and C18L viruses. In addition to the presence of distinct V1V2 heteroduplexes between viruses isolated from individuals, V1V2 heteroduplexes were also distinct between subjects.
###end p 31
###begin p 32
###xml 0 17 0 17 <bold xmlns:xlink="http://www.w3.org/1999/xlink">V1V2 HTA analysis</bold>
###xml 185 187 185 187 <sup xmlns:xlink="http://www.w3.org/1999/xlink">32</sup>
###xml 272 274 272 274 <sup xmlns:xlink="http://www.w3.org/1999/xlink">32</sup>
###xml 19 24 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 84 89 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
V1V2 HTA analysis. HIV-1 Env V1V2 regions were amplified by PCR from genomic DNA of HIV-1 infected PBMC and subjected to HTA analysis as described in the Methods. HTA analysis using a [32P]-labelled ADA V1V2 Env probe is shown in the left panel, and HTA analysis using a [32P]-labelled NL4-3 V1V2 Env probe is shown in the right panel. Similar results were obtained in three independent experiments.
###end p 32
###begin p 33
###xml 0 15 0 15 <bold xmlns:xlink="http://www.w3.org/1999/xlink">V3 HTA analysis</bold>
###xml 183 185 183 185 <sup xmlns:xlink="http://www.w3.org/1999/xlink">32</sup>
###xml 268 270 268 270 <sup xmlns:xlink="http://www.w3.org/1999/xlink">32</sup>
###xml 21 26 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 82 87 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
V3 HTA analysis. The HIV-1 Env V3 region was amplified by PCR from genomic DNA of HIV-1 infected PBMC and subjected to HTA analysis as described in the Methods. HTA analysis using a [32P]-labelled ADA V3 Env probe is shown in the left panel, and HTA analysis using a [32P]-labelled NL4-3 V3 Env probe is shown in the right panel. Similar results were obtained in three independent experiments.
###end p 33
###begin p 34
###xml 96 97 96 97 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4</xref>
###xml 516 517 516 517 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
###xml 779 783 779 783 <italic xmlns:xlink="http://www.w3.org/1999/xlink">nef </italic>
###xml 806 807 806 807 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 672 679 <span type="species:ncbi:9606">patient</span>
###xml 693 698 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 773 778 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 871 876 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
The V3 heteroduplex patterns also demonstrated distinct viral variants using either probe (Fig. 4). However, the resolution of V3 heteroduplexes was more readily achieved using the NL4-3 probe. V3 HTAs demonstrated 4 major variants in C18L that were distinct from a single variant present in C18E; 2 major variants in C98L that were distinct from a single major variant present in C98E; and 2 major variants in D36L that were distinct from 2 major variants present in D36E. Similar to results of the V1V2 HTAs (Fig. 3), the V3 heteroduplexes also appeared to be distinct between subjects. Together, the results of the V1V2 and V3 HTAs suggest significant inter- and intra-patient evolution of HIV-1 Env. In contrast to convergent sequence evolution previously reported for HIV-1 nef in the study subjects [4], the V1V2 and V3 HTA results suggest independent evolution of HIV-1 Env.
###end p 34
###begin title 35
V1V2 length polymorphism analysis
###end title 35
###begin p 36
###xml 166 168 166 168 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 296 298 296 298 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 299 301 299 301 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 451 452 451 452 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5</xref>
###xml 708 710 708 710 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 925 926 925 926 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5</xref>
###xml 19 24 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 279 284 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 342 347 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
The V1V2 region of HIV-1 Env contains extensive length polymorphisms, which can be utilized to compare the genetic relationships between different viral populations [41]. Furthermore, V2 region extensions have been associated with slow progression or long-term nonprogression of HIV-1 infection [23,42]. We further investigated the extent of HIV-1 Env diversity in SBBC viral isolates by measuring V1V2 length polymorphisms using GeneScan assay (Fig. 5). Although GeneScan analysis is unable to discriminate between distinct V1V2 variants of the same length which contain discrete amino acid substitutions, it has the sensitivity to detect a single nucleotide (nt) deletion or insertion within PCR products [41]. D36E virus contained 2 dominant V1V2 length polymorphisms measuring 271 and 277 nt, whereas D36L virus contained one dominant species measuring 280 nt and 4 minor species measuring 255, 268, 269 and 277 nt (Fig. 5). C98E and C98L viruses each contained single, dominant V1V2 length polymorphisms measuring 241 and 267 nt, respectively. C18E virus contained a single, dominant V1V2 length polymorphism measuring 241 nt, which was identical in nt length to the dominant species detected in C98E virus. However, C18L contained 5 distinct V1V2 length polymorphisms measuring 240, 247, 249, 250 and 252 nt. Thus, in each study subject, late viruses contained variants with V1V2 nt lengths that were distinct from those detected in early viruses.
###end p 36
###begin p 37
###xml 0 33 0 33 <bold xmlns:xlink="http://www.w3.org/1999/xlink">V1V2 length polymorphism analysis</bold>
###xml 39 44 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 152 157 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
V1V2 length polymorphism analysis. The HIV-1 Env V1V2 region incorporating a 6-carboxy-fluorescien fluorophore was amplified by PCR from genomic DNA of HIV-1 infected PBMC and subjected to GeneScan analysis, as described in the Methods and elsewhere [41, 56]. (A) GeneScan sample files generated from amplified products. (B) Fraction of sequences with a given V1V2 nucleotide length, which was calculated from GeneScan sample files. Peaks and bars shown in red represent V1V2 amplimers from early viruses, and peaks and bars shown in blue represent V1V2 amplimers from late viruses. Similar results were obtained in two independent experiments.
###end p 37
###begin p 38
###xml 176 177 176 177 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
###xml 761 763 761 763 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 764 766 764 766 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 688 693 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 791 796 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1169 1174 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
These results suggest that significant evolution of V1V2 Env occurred in each of the study subjects, an interpretation supported also by results of the V1V2 HTA analysis (Fig. 3). That C18E and C98E viruses contained dominant variants with identical V1V2 nt length raises the possibility that these 2 subjects once harboured Env variants with some shared features. However, the increase in number of V1V2 length polymorphisms in D36L and C18L viruses compared to D36E and C18E viruses, respectively, the shift in dominant V1V2 length polymorphism in C98 viruses, and the lack of overlap between V1V2 length variants detected in D36L, C98L and C18L viruses suggests divergent evolution of HIV-1 Env in these SBBC study subjects. In contrast to previous studies [23,42], long-term survival of HIV-1 infection in these subjects was not associated with increased V1V2 nt length. Furthermore, significant increases in V1V2 nt length diversity were observed in late viruses from a SP (D36) and a LTNP (C18) compared to respective early viruses, and no increase in V1V2 nt length diversity was observed in late virus from a SP (C98); this suggests that divergent evolution of HIV-1 Env in the study subjects was neither necessary nor sufficient for disease progression.
###end p 38
###begin title 39
Sequence analysis
###end title 39
###begin p 40
###xml 642 643 642 643 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6</xref>
###xml 965 966 965 966 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 397 402 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 894 899 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
The preceding studies showed differences in phenotype between D36, C98 and C18 viruses and evidence of divergent Env sequence evolution. However, an association between disease progression and results of phenotypic or genetic studies could not be made. To determine the genetic basis underlying differences in viral phenotype, and to better understand Env sequence changes which may contribute to HIV-1 progression in SBBC members, the gp120 region of Env was cloned and the V1 to V3 region of multiple, independent Envs sequenced. Phylogenetic analysis of interpatient sequence sets showed monophyletic clustering of D36 Env sequences (Fig. 6). The majority of C98 and C18 Env sequences clustered separately, but 1 C18 Env (C18L.3) clustered with C98 Envs, suggesting the presence of shared sequence similarities. This is not unexpected, since C18 and C98 were infected with a closely related HIV-1 strain and, unlike D36 whose virus had a coreceptor switch (Fig. 2), both C18 and C98 continued to harbor less evolved R5 variants. Analysis of intrapatient sequence sets showed that the majority of C18E and C98E clones cosegregated separately from C18L and C98L clones, respectively. However, clear cosegregation of D36E and D36L Envs in the monophyletic D36 cluster was not evident. Since phylogenetic analysis ignores sequence insertions and deletions, this suggests that Env sequence evolution in D36 may primarily involve nucleotide insertions and/or deletions rather than discrete substitutions.
###end p 40
###begin p 41
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Phylogenetic analysis</bold>
Phylogenetic analysis. Env nucleotide sequences were subjected to maximum likelihood analysis as described in the Methods. Branches labelled in green, blue and red represent sequences cloned from subjects C98, C18 and D36, respectively. E, clones from early viruses; L, clones from late viruses.
###end p 41
###begin p 42
###xml 105 107 105 107 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F7">7A</xref>
###xml 112 114 112 114 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F7">7B</xref>
###xml 368 369 368 369 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 436 438 436 438 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 658 660 658 660 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 661 663 661 663 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B45">45</xref>
###xml 1217 1219 1217 1219 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B46">46</xref>
###xml 1408 1410 1408 1410 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B47">47</xref>
###xml 347 352 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 839 844 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 893 898 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1151 1156 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Multiple sequence alignments of the V1V2 and V3 regions of Envs cloned from each virus are shown in Fig. 7A and 7B, respectively. The net charge of the V3 regions of D36E and D36L clones was +6, and the net charge of the V3 regions of C98E, C98L, C18E and C18L clones was +2 or +3. Consistent with results obtained in coreceptor usage assays with HIV-1 isolates (Fig. 2), coreceptor usage based on net V3 charge using the sinsi matrix [43] predicts D36E and D36L clones to be R5X4 phenotype, and C98E, C98L, C18E and C18L clones to be R5 phenotype. Although the presence of a basic residue at position 11 or 25 in V3 is strongly associated with CXCR4 usage [44,45], all D36E and D36L clones lacked basic residues at either position. Therefore, although D36E and D36L viruses are R5X4 phenotype in transfected Cf2th cells and use CXCR4 for HIV-1 entry into PBMC (data not shown), CXCR4 use for HIV-1 entry was not determined by the presence of charged amino acids at positions 11 or 25. Recently, the presence of isoleucine at amino acid 326 in V3, or proline or cysteine residues in V1 was shown to be important for macrophage (M) tropism of the R5X4 HIV-1 89.6 strain and other blood-derived, M-tropic R5X4 viruses [46]. In support of these results, D36E and D36L Envs lack these genetic changes, and the primary isolates replicate poorly in cultures of monocyte-derived macrophages (MDM) compared to 89.6 [47].
###end p 42
###begin p 43
###xml 0 36 0 36 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Env V1V2 and V3 amino acid sequences</bold>
###xml 38 43 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 236 241 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Env V1V2 and V3 amino acid sequences. HIV-1 Env amino acid sequences spanning the V1V2 (A) or V3 (B) regions of Env genes cloned into pGEM-T-easy were obtained as described in the Methods. Amino acid alignments are compared to Env from HIV-1 NL4-3. Dots indicate residues identical to NL4-3, and dashes indicate gaps.
###end p 43
###begin p 44
###xml 128 130 128 130 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F7">7A</xref>
###xml 265 267 265 267 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B48">48</xref>
###xml 381 383 381 383 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F7">7A</xref>
###xml 911 913 911 913 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B49">49</xref>
###xml 914 916 914 916 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B52">52</xref>
###xml 182 187 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 251 254 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 797 802 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1036 1041 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1075 1080 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1639 1644 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
The base of the V1V2 stem contains a highly conserved potential N-linked glycosylation site in the CNTS sequence of NL4-3 (Fig. 7A), which is present in all but seven of 208 clade B HIV-1 Env sequences screened from the Los Alamos National Laboratory HIV Database [48]. One of 3 D36E clones and 2/3 D36L clones lacked a potential N-linked glycosylation site at this position (Fig. 7A). Similarly, the glycosylation site at this position was lacking in 1/3 C98E and 1/3 C98L clones. In contrast, the glycosylation site at the V1V2 stem was conserved among all C18E and C18L clones, and in contrast to D36 and C98 clones there was a high degree of sequence homology in this region to that of NL4-3. Elimination of a glycosylation site at this position is sufficient for CD4-independent infection by HIV-1 ADA, achieved by altering the position of the V1V2 loops and exposing the coreceptor binding site in gp120 [49-52]. Thus, alterations in glycosylation at the V1V2 stem may serve to enhance receptor binding, which could contribute to HIV-1 pathogenicity at later stages of HIV-1 infection. To this end, it is interesting to note that Env clones lacking this glycosylation site were present only in SBBC slow progressors (D36 and C98), whereas the glycosylation site was present in all Envs from the LTNP (C18). Further sequence analysis of a greater number of Env clones is required to determine the significance of this sequence change in SBBC SPs and LTNPs. In addition, further studies to biologically characterize these Envs are required to determine whether SBBC Envs exhibit functional changes that could potentially contribute to HIV-1 pathogenicity.
###end p 44
###begin title 45
Conclusion
###end title 45
###begin p 46
###xml 572 576 572 576 <italic xmlns:xlink="http://www.w3.org/1999/xlink">nef </italic>
###xml 586 587 586 587 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 892 895 892 895 <italic xmlns:xlink="http://www.w3.org/1999/xlink">nef</italic>
###xml 62 67 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 904 909 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
In this study, we analyzed the phenotype and Env sequences of HIV-1 present in 3 SBBC members who were slow progressors or long-term nonprogressors. Early and late viruses from D36 were R5X4 whereas viruses isolated from C98 and C18 remained CCR5-restricted, indicating that a coreceptor switch was neither necessary nor sufficient for disease progression in these subjects. Replication capacity of these viruses in PBMC ranged from rapid to barely detectable and was not associated with disease progression. Although SBBC subjects had evidence of convergent evolution of nef sequence [4], analysis of Env diversity by V1V2 and V3 HTA, V1V2 length polymorphism assay, and maximum likelihood phylogeny suggest that Env sequence evolution was divergent in SP and LTNP subjects. Our results suggest that evolution toward a pathogenic Env phenotype may occur in long-term survivors infected with nef-deleted HIV-1, which is not necessarily associated with changes in replication capacity or coreceptor usage, or degree of Env sequence diversity.
###end p 46
###begin title 47
Methods
###end title 47
###begin title 48
###xml 13 18 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Isolation of HIV-1
###end title 48
###begin p 49
###xml 103 105 103 105 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 123 125 123 125 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6 </sup>
###xml 161 163 161 163 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6 </sup>
###xml 569 571 569 571 <sup xmlns:xlink="http://www.w3.org/1999/xlink">33</sup>
###xml 617 619 617 619 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B53">53</xref>
###xml 0 5 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 24 31 <span type="species:ncbi:9606">patient</span>
###xml 125 132 <span type="species:ncbi:9606">patient</span>
###xml 293 297 <span type="species:ncbi:9913">calf</span>
HIV-1 was isolated from patient's PBMC by coculture with selected PBMC according to published methods [36]. Briefly, 2 x 106 patient PBMC were mixed with 10 x 106 PHA-activated PBMC from 2 normal uninfected donors, and cocultured for 28 days in RPMI-1640 medium containing 10% (vol/vol) fetal calf serum (FCS) and 20 U/ml interleukin-2 (IL-2). Fifty percent media changes were performed twice weekly. Five million PHA-activated PBMC from a different donor were added at every second media change. Supernatants were tested for reverse transcriptase (RT) activity using [33P]dTTP incorporation as described previously [53]. Supernatants testing positive for RT activity were filtered through 0.45 mum filters and stored at -80degreesC.
###end p 49
###begin title 50
###xml 0 5 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
HIV-1 replication kinetics
###end title 50
###begin p 51
###xml 113 115 113 115 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6 </sup>
###xml 116 118 116 118 <sup xmlns:xlink="http://www.w3.org/1999/xlink">33</sup>
###xml 226 228 219 221 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 229 231 222 224 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B54">54</xref>
###xml 507 512 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Five hundred thousand PHA-activated PBMC were infected in 48-well tissue culture plates by incubation with 1 x 106 [33P] cpm RT units of virus supernatant in a volume of 250 mul for 3 h at 37degreesC, as described previously [32,54]. Virus was then removed, and PBMC were washed 3 times with phosphate-buffered saline (PBS) and cultured in RPMI-1640 medium containing 10% (vol/vol) FCS and 20 U/ml IL-2 for 27 days. Fifty percent medium changes were performed twice weekly, and supernatants were tested for HIV-1 replication by RT assays on days 1, 7, 14, 21 and 28 post-infection.
###end p 51
###begin title 52
Coreceptor usage
###end title 52
###begin p 53
###xml 172 174 172 174 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 175 177 175 177 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 178 180 178 180 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B54">54</xref>
###xml 181 183 181 183 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B55">55</xref>
###xml 399 401 397 399 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6 </sup>
###xml 402 404 400 402 <sup xmlns:xlink="http://www.w3.org/1999/xlink">33</sup>
###xml 28 33 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 423 428 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Coreceptor usage by primary HIV-1 isolates was determined using Cf2-Luc cells expressing CD4 alone, or expressing CD4 together with CCR5 or CXCR4, as described previously [32,36,54,55]. Briefly, Cf2-Luc cells were transfected with 10 mug of plasmid pcDNA3-CD4 and 20 mug of plasmid pcDNA3 containing CCR5 or CXCR4 using the calcium phosphate method, and infected 48 h later by incubation with 1 x 106 [33P] cpm RT units of HIV-1 in the presence of 2 mug of Polybrene (Sigma) per ml. After overnight infection, virus was removed and the cells were cultured for an additional 48 h prior to lysis in 200 mul of cell lysis buffer (Promega, Madison, Wis.). Cell lysates were cleared by centrifugation, and assayed for luciferase activity (Promega) according to the manufacturer's protocol.
###end p 53
###begin title 54
V1V2 and V3 HTA
###end title 54
###begin p 55
###xml 1488 1490 1454 1456 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 80 85 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 394 399 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1114 1119 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1222 1227 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
The V1V2 probes were generated by PCR amplification of a 282 bp fragment of the HIV-1 ADA or NL4-3 Env using primers SK122 (5'-CAAGCCTAAAGCCATGTGTA-3'; corresponding to nucleotide positions 6561 to 6580 of NL4-3) and SK123 (5'-TAATGTATGGGAATTGGCTCAA-3'; corresponding to nucleotide positions 6822 to 6843 of NL4-3). The V3 probes were generated by PCR amplification of a 239 bp fragment of the HIV-1 ADA or NL4-3 Env using primers V3c (5'-CCATAATAGTACAGCTGAATG-3'; corresponding to nucleotide positions 7062 to 7081 of NL4-3) and V3d (5'-ATTTCTGGGTCCCCTCCTGAGGATTG-3'; corresponding to nucleotide positions 7276 to 7301 of NL4-3). Labelling was achieved by incorporation of alpha- [32P]-dCTP in the PCR, which consisted of an initial denaturation at 95degreesC for 5 min, followed by 25 cycles of 95degreesC for 30 sec, 52degreesC for 1 min, and 72degreesC for 2 min followed by a final extension step of 72degreesC for 7 min. Unincorporated nucleotides were removed using a QIAquick spin column (Qiagen). The V1V2 and V3 Env target DNA sequences were generated from genomic DNA of PBMC infected with each primary HIV-1 isolate by PCR using primers SK122/SK123 and V3c/V3d, respectively. Genomic DNA of PBMC infected with HIV-1 ADA, NL4-3 or 89.6 was used as controls. PCR reactions proceeded as described above, except that radiolabelled dCTP was not included. Amplimers were purified using a QIAquick spin column (Qiagen). Heteroduplex reactions were performed as described previously [21] with the following modifications. The reactions consisted of 1x annealing buffer [1 M NaCl, 100 mM Tris-HCL (pH 7.5), 20 mM EDTA], 5 mul unlabelled V1V2 or V3 target PCR product, and 2.5 mul labelled V1V2 or V3 probe. The reactions were denatured at 95degreesC for 4 min and then allowed to anneal on wet ice for 5 min. The heteroduplexes were separated in 5.5% (wt/vol) polyacrylamide gels in 1x Tris-borate-EDTA buffer, and were visualized by autoradiography of dried HTA gels.
###end p 55
###begin title 56
V1V2 length polymorphism analysis
###end title 56
###begin p 57
###xml 133 135 133 135 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 598 600 598 600 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 1109 1111 1109 1111 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B56">56</xref>
###xml 1295 1297 1295 1297 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B57">57</xref>
###xml 29 34 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 162 167 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 277 282 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 393 398 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 469 474 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
V1V2 length polymorphisms in HIV-1 Env were quantified using a fluorescent-based assay that has been described in detail previously [41]. This technique measures HIV-1 sequence diversity by taking advantage of frequent length polymorphisms that occur within the V1V2 region of HIV-1 Env, and has the sensitivity to detect a single nucleotide deletion or insertion. Briefly, the V1V2 region of HIV-1 Env was amplified from genomic DNA of PBMC infected with each primary HIV-1 isolate by nested PCR using outer primers V12-51 and V12-52, and inner primers V12-50 and V12-53, as described previously [41]. The V12-50 primer used in the second round PCR was labelled with a fluorophore, 6-carboxy-fluorescien, at the 5' end (PE Biosystems). PCR amplified, fluorescently labelled products were purified using QIAquick spin columns (Qiagen), separated in 6% (wt/vol) denaturing polyacrylamide gels using an automated sequencer (ABI PRISM 377; PE Biosystems) and analysed using GeneScan software (PE Biosystems). Peaks with areas <10% of the total peak area were considered not significant, as described previously [56]. The fraction of sequences in the viral quasispecies with a given nucleotide length was calculated from GeneScan data and plotted against nucleotide length, as described previously [57].
###end p 57
###begin title 58
Env cloning, sequencing and phylogenetic analysis
###end title 58
###begin p 59
###xml 207 210 207 210 <italic xmlns:xlink="http://www.w3.org/1999/xlink">env</italic>
###xml 217 220 217 220 <italic xmlns:xlink="http://www.w3.org/1999/xlink">env</italic>
###xml 224 226 224 226 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B58">58</xref>
###xml 247 250 247 250 <italic xmlns:xlink="http://www.w3.org/1999/xlink">env</italic>
###xml 259 262 259 262 <italic xmlns:xlink="http://www.w3.org/1999/xlink">env</italic>
###xml 269 271 269 271 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B59">59</xref>
###xml 299 301 299 301 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B60">60</xref>
###xml 21 26 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 159 164 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 415 420 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
A 2.1 kb fragment of HIV-1 Env (corresponding to nucleotide positions 6332 to 8452 in NL4-3) was amplified from genomic DNA of PBMC infected with each primary HIV-1 isolate by nested PCR using outer primers env1A and env1M [58], and inner primers envKpnI and envBamHI [59], as described previously [60], and cloned into pGEM-T Easy (Promega). The V1 to V3 region of 2 to 3 independent Envs cloned from each primary HIV-1 isolate was sequenced using a SequiTherm EXCEL II DNA sequencing kit (Epicenter Technologies, Madison, WI) and a model 4000L LI-COR DNA sequencer (LI-COR, Lincoln, NE). Nucleotide sequences were aligned using CLUSTALW and corrected by hand. Phylogeny was estimated by a maximum likelihood algorithm (DNAml) with a transition/transversion ratio of 2.0, empirical base frequencies, and a randomised input order of sequences. Bootstrap values were calculated from 100 resamplings of the same alignment using Seqboot.
###end p 59
###begin title 60
Nucleotide sequence accession numbers
###end title 60
###begin p 61
The V1 to V3 Env nucleotide sequences reported here have been assigned GenBank accession numbers  to .
###end p 61
###begin title 62
Competing interests
###end title 62
###begin p 63
The author(s) declare that they have no competing interests.
###end p 63
###begin title 64
Authors' contributions
###end title 64
###begin p 65
###xml 255 260 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 300 307 <span type="species:ncbi:9606">patient</span>
###xml 477 482 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
LG carried out the virus replication studies, DNA sequencing and sequence analysis, and the GeneScan analyses; JS, MJC and KW carried out the HTA studies; ALC assisted with the HTA studies; MJC and JS assisted with the DNA sequencing; DAM carried out the HIV-1 virus isolations; JCL and JSS provided patient samples and clinical data; MJC, SLW, DG, ALC and DAM contributed to the study design, assisted with manuscript preparation, and helped edit the manuscript; DG undertook HIV-1 coreceptor testing in conjunction with PRG; MJC, SLW, DG, ALC, DAM and PRG analyzed and interpreted the data; PRG designed and oversaw the study, and wrote the manuscript. All authors read and approved the manuscript.
###end p 65
###begin title 66
Acknowledgements
###end title 66
###begin p 67
We thank J. Sodroski and B. Etemad-Moghadam for providing Cf2-Luc cells, and J. Sodroski for providing CD4 and coreceptor plasmids. This study was supported, in part, by a grant from the National Health and Medical Research Council of Australia (NHMRC) to PRG (251520), a grant from the American Foundation for AIDS Research (amfAR) to DAM (106669), and grants from the National Institutes of Health to PRG (AI054207) and DG (NS37277). LG and JS are recipients of NHMRC Dora Lush Biomedical Research Scholarships. PRG is the recipient of an NHMRC R. Douglas Wright Biomedical Career Development Award.
###end p 67
###begin article-title 68
###xml 52 57 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Genomic structure of an attenuated quasi species of HIV-1 from a blood transfusion donor and recipients
###end article-title 68
###begin article-title 69
###xml 22 27 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Long-term symptomless HIV-1 infection in recipients of blood products from a single donor
###end article-title 69
###begin article-title 70
###xml 96 101 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Immunologic and virologic status after 14 to 18 years of infection with an attenuated strain of HIV-1. A report from the Sydney Blood Bank Cohort
###end article-title 70
###begin article-title 71
###xml 25 60 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Longitudinal analysis of human immunodeficiency virus type 1 nef/long terminal repeat sequences in a cohort of long-term survivors infected from a single source
###end article-title 71
###begin article-title 72
###xml 34 37 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Pathogenesis of macrophage tropic HIV
###end article-title 72
###begin article-title 73
###xml 23 28 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease
###end article-title 73
###begin article-title 74
###xml 44 47 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
The plasma membrane as a combat zone in the HIV battlefield
###end article-title 74
###begin article-title 75
###xml 93 98 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1
###end article-title 75
###begin article-title 76
###xml 75 80 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates
###end article-title 76
###begin article-title 77
###xml 62 67 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Identification of a major co-receptor for primary isolates of HIV-1
###end article-title 77
###begin article-title 78
###xml 22 27 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors
###end article-title 78
###begin article-title 79
###xml 0 5 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5
###end article-title 79
###begin article-title 80
###xml 0 5 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor
###end article-title 80
###begin article-title 81
###xml 28 63 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype
###end article-title 81
###begin article-title 82
###xml 79 84 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Change in coreceptor use coreceptor use correlates with disease progression in HIV-1--infected individuals
###end article-title 82
###begin article-title 83
###xml 66 71 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 95 103 <span type="species:ncbi:9606">patients</span>
Coreceptor usage and RANTES sensitivity of non-syncytium-inducing HIV-1 isolates obtained from patients with AIDS
###end article-title 83
###begin article-title 84
###xml 81 116 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Adaptation to promiscuous usage of chemokine receptors is not a prerequisite for human immunodeficiency virus type 1 disease progression
###end article-title 84
###begin article-title 85
###xml 80 115 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Divergent patterns of progression to AIDS after infection from the same source: human immunodeficiency virus type 1 evolution and antiviral responses
###end article-title 85
###begin article-title 86
###xml 0 35 <span type="species:ncbi:11676">Human immunodeficiency virus type 1</span>
###xml 57 65 <span type="species:ncbi:9606">children</span>
Human immunodeficiency virus type 1 genetic evolution in children with different rates of development of disease
###end article-title 86
###begin article-title 87
###xml 20 55 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Slower evolution of human immunodeficiency virus type 1 quasispecies during progression to AIDS
###end article-title 87
###begin article-title 88
###xml 0 35 <span type="species:ncbi:11676">Human immunodeficiency virus type 1</span>
Human immunodeficiency virus type 1 evolution in vivo tracked by DNA heteroduplex mobility assays
###end article-title 88
###begin article-title 89
###xml 10 45 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Intrahost human immunodeficiency virus type 1 evolution is related to length of the immunocompetent period
###end article-title 89
###begin article-title 90
###xml 32 67 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
In vivo sequence variability of human immunodeficiency virus type 1 envelope gp120: association of V2 extension with slow disease progression
###end article-title 90
###begin article-title 91
###xml 72 102 <span type="species:ncbi:11676">human immunodeficiency virus 1</span>
Evolution of sequences encoding the principal neutralization epitope of human immunodeficiency virus 1 is host dependent, rapid, and continuous
###end article-title 91
###begin article-title 92
###xml 22 50 <span type="species:ncbi:12721">human immunodeficiency virus</span>
Adaptive evolution of human immunodeficiency virus-type 1 during the natural course of infection
###end article-title 92
###begin article-title 93
###xml 0 5 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
HIV-1 isolates are rapidly evolving quasispecies: evidence for viral mixtures and preferred nucleotide substitutions
###end article-title 93
###begin article-title 94
###xml 12 17 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Patterns of HIV-1 evolution in individuals with differing rates of CD4 T cell decline
###end article-title 94
###begin article-title 95
###xml 16 51 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Relationship of human immunodeficiency virus type 1 sequence heterogeneity to stage of disease
###end article-title 95
###begin article-title 96
###xml 73 108 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection
###end article-title 96
###begin article-title 97
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human Immunodeficiency Virus Type 1 env Evolves toward Ancestral States upon Transmission to a New Host
###end article-title 97
###begin article-title 98
###xml 77 112 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Persistent CCR5 utilization and enhanced macrophage tropism by primary blood human immunodeficiency virus type 1 isolates from advanced stages of disease and comparison to tissue-derived isolates
###end article-title 98
###begin article-title 99
###xml 58 63 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 135 138 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Longitudinal analysis of nef/long terminal repeat-deleted HIV-1 in blood and cerebrospinal fluid of a long-term survivor who developed HIV-associated dementia
###end article-title 99
###begin article-title 100
###xml 32 60 <span type="species:ncbi:12721">human immunodeficiency virus</span>
Coreceptor phenotype of natural human immunodeficiency virus with nef deleted evolves in vivo, leading to increased virulence
###end article-title 100
###begin article-title 101
###xml 68 97 <span type="species:ncbi:11723">simian immunodeficiency virus</span>
###xml 118 132 <span type="species:ncbi:9544">rhesus monkeys</span>
Determinants of increased replicative capacity of serially passaged simian immunodeficiency virus with nef deleted in rhesus monkeys
###end article-title 101
###begin article-title 102
###xml 56 61 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
In vivo replication kinetics of a nef-deleted strain of HIV-1
###end article-title 102
###begin article-title 103
###xml 22 27 <span type="species:ncbi:9606">Human</span>
Macrophage Tropism of Human Immunodeficiency Virus Type 1 Isolates from Brain and Lymphoid Tissues Predicts Neurotropism Independent of Coreceptor Specificity
###end article-title 103
###begin article-title 104
###xml 39 44 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor
###end article-title 104
###begin article-title 105
###xml 23 26 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Inhibition of T-tropic HIV strains by selective antagonization of the chemokine receptor CXCR4
###end article-title 105
###begin article-title 106
###xml 83 88 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity
###end article-title 106
###begin article-title 107
###xml 34 69 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Preferential use of CXCR4 by R5X4 human immunodeficiency virus type 1 isolates for infection of primary lymphocytes
###end article-title 107
###begin article-title 108
###xml 39 44 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Genetic characterization of rebounding HIV-1 after cessation of highly active antiretroviral therapy
###end article-title 108
###begin article-title 109
###xml 0 5 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
HIV-1 strains from a cohort of American subjects reveal the presence of a V2 region extension unique to slow progressors and non-progressors
###end article-title 109
###begin article-title 110
###xml 106 141 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Improved coreceptor usage prediction and genotypic monitoring of R5-to-X4 transition by motif analysis of human immunodeficiency virus type 1 env V3 loop sequences
###end article-title 110
###begin article-title 111
###xml 125 130 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Patterns of amino acid variability in NSI-like and SI-like V3 sequences and a linked change in the CD4-binding domain of the HIV-1 Env protein
###end article-title 111
###begin article-title 112
###xml 41 46 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Envelope V3 amino acid sequence predicts HIV-1 phenotype (co-receptor usage and tropism for macrophages)
###end article-title 112
###begin article-title 113
###xml 24 29 <span type="species:ncbi:9606">Human</span>
Complex Determinants in Human Immunodeficiency Virus Type 1 Envelope gp120 Mediate CXCR4-Dependent Infection of Macrophages
###end article-title 113
###begin article-title 114
###xml 40 45 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Macrophage tropism and cytopathicity of HIV-1 variants isolated sequentially from a long-term survivor infected with nef-deleted virus.
###end article-title 114
###begin article-title 115
###xml 83 118 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Increased CCR5 affinity and reduced CCR5/CD4 dependence of a neurovirulent primary human immunodeficiency virus type 1 isolate
###end article-title 115
###begin article-title 116
###xml 56 91 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Loss of a single N-linked glycan allows CD4-independent human immunodeficiency virus type 1 infection by altering the position of the gp120 V1/V2 variable loops
###end article-title 116
###begin article-title 117
###xml 56 84 <span type="species:ncbi:12721">human immunodeficiency virus</span>
Increased neutralization sensitivity of CD4-independent human immunodeficiency virus variants
###end article-title 117
###begin article-title 118
###xml 31 34 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
The antigenic structure of the HIV gp120 envelope glycoprotein
###end article-title 118
###begin article-title 119
###xml 47 82 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Functional and immunologic characterization of human immunodeficiency virus type 1 envelope glycoproteins containing deletions of the major variable regions
###end article-title 119
###begin article-title 120
###xml 11 16 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 30 35 <span type="species:ncbi:9606">human</span>
Restricted HIV-1 infection of human astrocytes: potential role of nef in the regulation of virus replication
###end article-title 120
###begin article-title 121
###xml 31 66 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
###xml 68 73 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 148 153 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 168 176 <span type="species:ncbi:9606">patients</span>
Uncoupling coreceptor usage of human immunodeficiency virus type 1 (HIV-1) from macrophage tropism reveals biological properties of CCR5-restricted HIV-1 isolates from patients with acquired immunodeficiency syndrome
###end article-title 121
###begin article-title 122
###xml 27 32 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Persistence of dual-tropic HIV-1 in an individual homozygous for the CCR5 Delta 32 allele
###end article-title 122
###begin article-title 123
###xml 72 75 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Analysis of length variation in the V1-V2 region of env in nonsubtype B HIV type 1 from Uganda
###end article-title 123
###begin article-title 124
###xml 46 51 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission
###end article-title 124
###begin article-title 125
###xml 65 100 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
###xml 163 166 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Molecular cloning and analysis of functional envelope genes from human immunodeficiency virus type 1 sequence subtypes A through G. The WHO and NIAID Networks for HIV Isolation and Characterization
###end article-title 125
###begin article-title 126
###xml 35 40 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
CCR3 and CCR5 are co-receptors for HIV-1 infection of microglia
###end article-title 126
###begin article-title 127
###xml 47 82 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
###xml 125 133 <span type="species:ncbi:9606">patients</span>
Genetic and functional analysis of full-length human immunodeficiency virus type 1 env genes derived from brain and blood of patients with AIDS
###end article-title 127

